Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C30H31FN2O |
Molar mass | 454.589 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Siramesine (or Lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype. [1] In animal studies, siramesine has been shown to produce anxiolytic [2] and antidepressant [3] effects. It was developed by the pharmaceutical company H Lundbeck for the treatment of anxiety, [4] although development was discontinued after clinical trials showed a lack of efficacy in humans. Siramesine has been shown to produce an enhanced antidepressant effect when co-administered with NMDA antagonists. [5] It has also been used to study the σ2 activity of cocaine, [6] and has been shown to produce anticancer properties both in vitro [7] and in vivo. [8]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C30H31FN2O |
Molar mass | 454.589 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Siramesine (or Lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype. [1] In animal studies, siramesine has been shown to produce anxiolytic [2] and antidepressant [3] effects. It was developed by the pharmaceutical company H Lundbeck for the treatment of anxiety, [4] although development was discontinued after clinical trials showed a lack of efficacy in humans. Siramesine has been shown to produce an enhanced antidepressant effect when co-administered with NMDA antagonists. [5] It has also been used to study the σ2 activity of cocaine, [6] and has been shown to produce anticancer properties both in vitro [7] and in vivo. [8]